Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
462 hedge funds and large institutions have $25.3B invested in Alexion Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 167 increasing their positions, 169 reducing their positions, and 39 closing their positions.
103% more call options, than puts
Call options by funds: $260M | Put options by funds: $128M
72% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 39
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
16% more capital invested
Capital invested by funds: $21.8B → $25.3B (+$3.44B)
6% more funds holding
Funds holding: 437 → 462 (+25)
1% less repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 169
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$209M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$180M |
| 3 |
JP Morgan Chase
New York
|
+$128M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$75.8M |
| 5 |
Millennium Management
New York
|
+$60.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$152M |
| 2 |
YCMGA
York Capital Management Global Advisors
New York
|
-$127M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$76.4M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$69.3M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$68.4M |
ALXN Hedge Fund Activity: Q4 2013 in Review
462 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2013, worth a combined $25.3B — up 16% from $21.8B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new ALXN positions and 39 closed out — a net gain of 28 holders — while 167 added to existing stakes and 169 trimmed.
The largest buyer was Wells Fargo, adding an estimated $209M. The largest seller was Citadel Advisors, cutting an estimated $152M.
- 462 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2013, up from 437 in Q3 2013.
- Funds reported $25.3B of Alexion Pharmaceuticals stock for Q4 2013, up 16% quarter-over-quarter.
- 67 funds opened new Alexion Pharmaceuticals positions in Q4 2013 and 39 closed out, a net change of +28 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2013 was Wells Fargo, an estimated $209M added.
- The largest Alexion Pharmaceuticals seller in Q4 2013 was Citadel Advisors, an estimated $152M sold.
Based on aggregated 13F filings for Q4 2013.